Xanomeline: the first study of the safety and efficacy of an M1 agonist in mild and moderate Alzheimer's disease

By Bodick N.C.   Offen W.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 205-205

Elsevier

Access to resources Recommend Favorite

Novel persistent activation of muscarinic M 1 receptors by xanomeline

By Christopoulos A.   El-Fakahany E.E.  

European Journal of Pharmacology, Vol. 334, Iss. 1, 1997-09 ,pp. : 3-4

Elsevier

Access to resources Recommend Favorite

Rivastigmine Transdermal Patch Skin Tolerability: Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease

By Cummings Jeffrey L.  

Clinical Drug Investigation, Vol. 30, Iss. 1, 2010-01 ,pp. : 41-49

Adis International

Access to resources Recommend Favorite

Idebenone: A Review of its Use in Mild to Moderate Alzheimer's Disease

By Adkins J.C.   Noble S.  

CNS Drugs, Vol. 9, Iss. 5, 1998-05 ,pp. : 403-419

Adis International

Access to resources Recommend Favorite

Nicergoline in the Treatment of Mild-to-Moderate Alzheimer's Disease: A European Multicentre Trial

By Winblad B.  

Clinical Drug Investigation, Vol. 21, Iss. 9, 2001-09 ,pp. : 621-632

Adis International

Access to resources Recommend Favorite